Medico Remedies Ltd

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Medico Remedies Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, reflecting evolving investor perceptions amid a challenging market backdrop. This recalibration in price-to-earnings and price-to-book ratios, alongside peer comparisons, offers fresh insights into the stock’s price attractiveness and potential investment appeal.

Medico Remedies Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside comparative analysis with industry peers. Investors and analysts alike are reassessing the stock’s price attractiveness in light of these developments.

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Medico Remedies Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹390.02 crores, reported a robust top-line performance in Q3 FY26 with net sales surging 48.59% year-on-year to ₹58.68 crores. However, the quarter revealed a concerning trend in profitability metrics, with net profit at ₹2.87 crores showing sequential growth of 11.67% but masking deeper operational challenges. The stock has faced significant headwinds over the past year, declining 30.89% whilst trading at ₹47.00, approximately 35% below its 52-week high of ₹71.98.

Medico Remedies Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade as of late December 2025. This recalibration reflects evolving market perceptions amid fluctuating financial metrics and sector dynamics, prompting investors to reassess the stock’s price attractiveness relative to its historical averages and peer group.

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 23 Jan 2026, registering a maximum daily gain of 10.0%. This sharp rally was driven by strong buying interest, significant volume expansion, and a notable increase in delivery volumes, signalling heightened investor confidence despite a recent downgrade in its mojo grade.

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 22 Jan 2026, propelled by strong buying momentum and heightened investor participation. The stock closed at ₹49.31, marking a near 10% gain on the day, significantly outperforming its sector and benchmark indices amid a volatile trading session.

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 December 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 12 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Medico Remedies Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 30 December 2025. This adjustment reflects a nuanced reassessment across quality, valuation, financial trends, and technical indicators, signalling a more cautious stance despite the company’s solid financial performance and operational strengths.

Medico Remedies Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 24 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the most up-to-date view of the company’s fundamentals, returns, and technical outlook.

Medico Remedies Ltd witnessed a significant surge in its share price on 23 Dec 2025, hitting the upper circuit limit of 10%, reflecting intense buying interest and robust market participation. The stock outperformed its sector and broader indices, signalling heightened investor enthusiasm in this micro-cap pharmaceutical player.

Medico Remedies, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment following a detailed evaluation of its quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent changes in the company’s analytical perspective, providing investors with a comprehensive understanding of its current standing.